A PET scan to find hidden spread in slow-growing breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing a special PET scan (18F-FES PET/CT) to see if it can find distant cancer spread in women with a slow-growing, estrogen receptor-positive, stage III breast cancer. The goal is to find out whether this imaging test can detect hidden metastases better than standard scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have been diagnosed with invasive breast cancer within the last 90 days.
- Your breast cancer is estrogen receptor-positive and slow-growing (low or intermediate grade).
- Your breast cancer is stage IIIA to IIIC (locally advanced, but not yet spread to distant organs).
- You have had or will have a chest CT, abdominal CT, and bone scan within the last 90 days.
- Your performance status is good (able to carry out daily activities without major limitations).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
This study tests whether a special PET scan and a blood test can help predict how well hormone therapy will work for people with metastatic breast cancer. The goal is to find better ways to personalize treatment.
This Phase 2 study tests how well a special PET/CT scan (called FES PET/CT) can find uterine cancer and its spread. It may help doctors see where cancer is active, which can guide future treatment decisions.
This trial uses a special imaging scan called 18F-FES PET/CT to help doctors plan treatment and check how well it works for breast cancer that is ER-positive (meaning the cancer cells grow in response to estrogen). It may help improve treatment choices and monitoring.
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
Hear when a new Stage III Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.